kimyrsa.com Open in urlscan Pro
23.96.252.42  Public Scan

Form analysis
0 forms found in the DOM

Text Content

THIS WEBSITE USES COOKIES TO ENHANCE YOUR BROWSING EXPERIENCE.

By continuing, you give us permission to deploy cookies as per our privacy and
cookies policy.

I UNDERSTAND

This site is intended for US Healthcare Professionals only.

 * Important Safety Information
 * Full Prescribing Information
 * Medical Information

 * Treatment
   Landscape
    * ABSSSI
      Treatment
      Burden
      
    * ABSSSI
      Treatment
      Challenges
      

 * About
   KIMYRSA®
    * What is
      KIMYRSA®?
      
    * Mechanisms
      of Action
      
    * PK Profile
      
    * In Vitro
      Results by Pathogen
      

 * Clinical
   Studies
    * Clinical Study Information
      
    * SOLO Studies
      
    * Real-World Studies
      

 * Single-Dose
   Administration
   
 * Ordering
   Information
   
 * Resources
   and Support
    * Billing and Coding
      
    * Support Programs
      
    * Patient Education
      

 * Medical Information
   

×
 
 

CHOOSE KIMYRSA FOR YOUR ABSSSI PATIENTS

KIMRSA PROVIDES PROVEN EFFICACY AND CONSISTENT REAL-WORLD OUTCOMES WITH THE
ASSURANCE OF AMPLE SUPPLY FOR ALL YOUR APPROPRIATE PATIENTS.

LEARN MORE ABOUT MELINTA'S COMMITMENT TO PRODUCT SUPPLY


BACK TO EVERYDAY


HELP THEM ESCAPE THE LIMITS OF MULTIDOSE IV THERAPY



Treat ABSSSI, including cellulitis, abscesses, and wound infections, with
KIMYRSA®— a single-dose 1-hour infusion therapy that helps patients avoid the
obstacles of multidose IV treatments.1,2*

FIND OUT HOW


BACK TO WORK


HELP THEM ESCAPE THE LIMITS OF MULTIDOSE IV THERAPY



Treat ABSSSI, including cellulitis, abscesses, and wound infections, with
KIMYRSA®— a single-dose 1-hour infusion therapy that helps patients avoid the
obstacles of multidose IV treatments.1,2*

FIND OUT HOW


BACK TO EVERYDAY


HELP THEM ESCAPE THE LIMITS OF MULTIDOSE IV THERAPY



Treat ABSSSI, including cellulitis, abscesses, and wound infections, with
KIMYRSA®— a single-dose 1-hour infusion therapy that helps patients avoid the
obstacles of multidose IV treatments.1,2*

FIND OUT HOW


BACK TO WORK


HELP THEM ESCAPE THE LIMITS OF MULTIDOSE IV THERAPY



Treat ABSSSI, including cellulitis, abscesses, and wound infections, with
KIMYRSA®— a single-dose 1-hour infusion therapy that helps patients avoid the
obstacles of multidose IV treatments.1,2*

FIND OUT HOW


A single infusion ensures adherence to a full course of therapy1

Eliminate noncompliance

Short-acting multiday IV treatments may not be the best option for every patient

See how KIMYRSA® CAN BENEFIT Your Patients

Find out how to get KIMYRSA® for your patients

Get access information

References: 1. Kimyrsa. Package insert. Melinta Therapeutics; 2021. 2. Jin J,
Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a
review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-286.
doi:10.2147/tcrm.s1458


*INDICATION AND USAGE

 * Both KIMYRSA® and ORBACTIV® are oritavancin products that are indicated for
   the treatment of adult patients with acute bacterial skin and skin structure
   infections (ABSSSI) caused or suspected to be caused by susceptible isolates
   of the following gram-positive microorganisms: Staphylococcus aureus
   (including methicillin-susceptible [MSSA] and methicillin-resistant [MRSA]
   isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus
   dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S.
   intermedius, and S. constellatus), and Enterococcus faecalis
   (vancomycin-susceptible isolates only).
 * To reduce the development of drug-resistant bacteria and maintain the
   effectiveness of oritavancin and other antibacterial drugs, oritavancin
   should be used only to treat or prevent infections that are proven or
   strongly suspected to be caused by susceptible bacteria.
 * KIMYRSA® and ORBACTIV® are not approved for combination use and have
   differences in dose strength, duration of infusion, and preparation
   instructions, including reconstitution and dilution instructions and
   compatible diluents. Please see the full Prescribing Information for each
   product.


IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

 * Use of intravenous unfractionated heparin sodium is contraindicated for 120
   hours (5 days) after oritavancin administration because the activated partial
   thromboplastin time (aPTT) test results may remain falsely elevated for
   approximately 120 hours (5 days) after oritavancin administration.
 * Oritavancin products are contraindicated in patients with known
   hypersensitivity to oritavancin.

WARNINGS AND PRECAUTIONS

 * Coagulation test interference: Oritavancin has been shown to artificially
   prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12
   hours and ACT for up to 24 hours. Oritavancin has also been shown to elevate
   D-dimer concentrations up to 72 hours. For patients who require aPTT
   monitoring within 120 hours of oritavancin dosing, consider a
   non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic)
   assay or an alternative anticoagulant not requiring aPTT.
 * Serious hypersensitivity reactions, including anaphylaxis, have been reported
   with the use of oritavancin products. Discontinue infusion if signs of acute
   hypersensitivity occur. Closely monitor patients with known hypersensitivity
   to glycopeptides.
 * Infusion related reactions: Infusion reactions characterized by chest pain,
   back pain, chills and tremor have been observed with the use of oritavancin
   products, including after the administration of more than one dose of
   oritavancin during a single course of therapy. Stopping or slowing the
   infusion may result in cessation of these reactions.
 * Clostridioides difficile-associated diarrhea: Evaluate patients if diarrhea
   occurs.
 * Concomitant warfarin use: Oritavancin has been shown to artificially prolong
   PT/INR for up to 12 hours. Patients should be monitored for bleeding if
   concomitantly receiving oritavancin products and warfarin.
 * Osteomyelitis: Institute appropriate alternate antibacterial therapy in
   patients with confirmed or suspected osteomyelitis.
 * Prescribing oritavancin products in the absence of a proven or strongly
   suspected bacterial infection or a prophylactic indication is unlikely to
   provide benefit to the patient and increases the risk of development of
   drug-resistant bacteria.

ADVERSE REACTIONS

 * The most common adverse reactions (≥3%) in patients treated with oritavancin
   products were headache, nausea, vomiting, limb and subcutaneous abscesses,
   and diarrhea. The adverse reactions occurring in ≥2 patients receiving
   KIMYRSA® were hypersensitivity, pruritus, chills and pyrexia.

Please see Full Prescribing Information for ORBACTIV®.

Please see Full Prescribing Information for KIMYRSA®.

Medical Information

For medical inquiries or to report an adverse event, other safety related
information, or product complaints for a company product, please contact Medical
Information.

medinfo@melinta.com
1-844-MED-MLNT (1-844-633-6568)
https://www.melintamedicalinformation.com

 * Melinta Corporate
 * Privacy Policy
 * Terms of Use
 * ORBACTIV® (oritavancin)

©2022 Melinta Therapeutics. All Rights Reserved. 11/2022 PP-KIM-US-0128

SEE MORE

*INDICATION AND USAGE

Both KIMYRSA® and ORBACTIV® are oritavancin products that are indicated for the
treatment of adult patients with acute bacterial skin and skin structure
infections (ABSSSI) caused or suspected to be

IMPORTANT SAFETY INFORMATION

ContraindicationsUse of intravenous unfractionated heparin sodium is
contraindicated for 120 hours (5 days) after oritavancin

CLick